ePharmaSolutions

ePharmaSolutions provides innovative solutions designed to optimize clinical trials, enhancing operational efficiency and participant safety through a range of integrated services and technologies. ePharmaSolutions focuses on delivering clinical trial solutions that enhance the efficiency and safety of research processes. The company has undergone a strategic transformation since its inception. Located in Plymouth Meeting, US, it was acquired in September 2014 by WIRB – Copernicus Group, Inc.

, which is associated with Arsenal Capital Partners and AXA Private Equity. Lance Converse serves as CEO and is pivotal in the company's operational direction. WCGclinical. com, which fully integrates ePharmaSolutions, offers a comprehensive suite of solutions aimed at enhancing the efficiency and safety of clinical trials.

Their core products include services that facilitate protocol design, participant recruitment, data monitoring, and independent review processes. Key offerings such as IRB (Institutional Review Board) Review, IBC (Institutional Biosafety Committee) Review, and Total Feasibility services ensure that clinical trials adhere to regulatory requirements while prioritizing participant safety. The company targets a diverse client base that includes pharmaceutical companies, biotechnology firms, and academic research institutions across North America, Europe, and Asia-Pacific. Their tools and technologies, such as ClinSphere™, AIMS®, and CTMS (Clinical Trial Management System), are utilized globally to streamline operations and improve trial outcomes.

The revenue model of WCGclinical. com is based on providing various clinical trial services, primarily through subscription-based partnerships and direct service agreements with clients. Income is generated from fees associated with offerings, including IRB Review and Total Enrollment services. Clients engage WCG for a range of services tailored to their specific trial needs, with transactions structured around service contracts and licensing agreements.

Pricing for these services is determined by the scope of the trial, the complexity of the services required, and the duration of the engagement, facilitating seamless interactions with clients throughout the clinical trial process. The company's future growth strategy involves launching new products and expanding its market presence. While specific upcoming product details are not disclosed, ePharmaSolutions aims to enhance its offerings for improved clinical trial efficiency. The company is also focused on expanding into new geographical regions, although specific target markets have not been mentioned.

The acquisition by WIRB – Copernicus Group in September 2014 is expected to provide the necessary support to bolster these initiatives, although the financial terms of the acquisition have not been disclosed.